Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
GELARC (Gel-Arc Ltd) was a biotechnology company that specialized in the development of advanced hydrogel-based architectures for regenerative medicine and 3D cell culture applications. Spun out from the University of Nottingham, the company utilized a proprietary platform to create structured, injectable scaffolds that mimic the natural extracellular matrix to support tissue repair and drug delivery. Their technology was primarily focused on enhancing the efficacy of cell therapies and promoting healing in indications such as bone repair and chronic wounds. While the company provided innovative tools for researchers and clinicians, it is no longer active as an independent entity.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on GELARC.